Eli Lilly (LLY)

[behappyalways]

How $LLY makes money
https://twitter.com/Mayhem4Markets/stat ... 2878220636

[behappyalways]

"Breakthrough" Eli Lilly Weight-Loss Drug Data To Treat Obesity & Sleep Apnea, Sends CPAP Device-Makers Plunging
https://www.zerohedge.com/markets/break ... pap-device

[behappyalways]

New Study Reveals Ozempic, Wegovy Linked To 'Potentially Blinding Eye Condition'
https://www.zerohedge.com/medical/new-s ... -condition

[behappyalways]

How $LLY makes money
https://x.com/Mayhem4Markets/status/1822384307991961685

[behappyalways]

Did The 'Fatty Bubble' Pop? Eli Lilly Discounts Low-Dose Zepbound Vials By 50%
https://www.zerohedge.com/medical/did-f ... e_vignette

[winston]

not vested

Eli Lilly shares tumble as Q3 misses estimates, guidance lowered

by Sam Boughedda

Posted adjusted earnings per share of $1.18, missing the consensus estimate of $1.45.

Revenue came in at $11.44 billion, below analyst projections of $12.09 billion.

Despite falling short of expectations, revenue grew 20% YoY, boosted by strong sales of diabetes drug Mounjaro and weight loss treatment Zepbound. E

Eli Lilly also cut its 2024 adjusted EPS outlook to between $13.02 and $13.52, compared to the $13.50 consensus estimate.

Source: investing.com

https://www.investing.com/news/stock-ma ... s_headline

[winston]

not vested

Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip

by Keith Speights

Lilly's Q3 revenue and earnings miss primarily stemmed from lower-than-expected sales of Mounjaro and Zepbound.

Wholesalers decreased their inventories of the type 2 diabetes and obesity drugs in Q3.

Demand for Mounjaro and Zepbound "remains strong and growing." Lilly CEO David Ricks noted that U.S. prescription volume for the drugs jumped 25% from Q2 to Q3.

Zepbound remains in the early stages of its launch.

New international launches for Mounjaro should contribute to growth in Q4.

Sales for breast cancer drug Verzenio jumped 32% year over year to $1.37 billion in Q3.

Meanwhile, autoimmune disease drug Taltz continued to enjoy strong momentum, with sales rising 18% to nearly $880 million.

Even Lilly's insulin product Humalog, which was first approved by the U.S. Food and Drug Administration (FDA) way back in 1996, delivered year-over-year sales growth of 35%.

The FDA approved Kisunla as a treatment for Alzheimer's disease in July and Ebglyss in treating atopic dermatitis in September.

Oral obesity drug orforglipron is currently in phase 2 testing. Ricks pointed out that Lilly is in the lead position in developing an oral obesity drug. He noted that oral products are probably the best solution for many of the "potential 1 billion customers on the planet."

Lilly could submit orforglipron for approval and launch the drug in less than two years, if clinical studies go well.

Trade at nearly 37.5 times forward earnings.

Source: The Motley Fool

https://finance.yahoo.com/news/why-eli- ... 00722.html

[winston]

not vested

Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?

by David Jagielski

Demand is strong, but Eli Lilly says as it was fulfilling back orders to wholesalers for Mounjaro and Zepbound, they didn't end up ordering more supply and simply used their existing stock.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall within a range of $13.02 and $13.52 (the previous forecast was $16.10 to $16.60).

Forward price-to-earnings multiple of 36.

If you're a long-term investor, I don't think there's much to worry about with Eli Lilly. The stock is still expensive, but given the long-term potential it has with Mounjaro and Zepbound potentially delivering billions in revenue for years to come, its earnings could catch up to its valuation over time.

Source: The Motley Fool

https://finance.yahoo.com/news/eli-lill ... 00934.html

[winston]

not vested

Growth Stocks to Buy on the Dip

by Prosper Junior Bakiny

Eli Lilly has been making quite a bit of noise thanks to its work in diabetes and obesity.

Investors turned on the company, though, after its third-quarter earnings. Why? The pharmaceutical giant failed to match expectations. Its revenue increased by “only” 20% year over year to $11.4 billion.

Eli Lilly’s newest medicines for diabetes and obesity, Mounjaro and Zepbound, respectively, apparently didn’t live up to the hype during the period.

Mounjaro’s sales came in at $3.1 billion, up 121% compared to the year-ago period.

Zepbound, which earned the nod in November 2023, generated $1.3 billion in sales. Those are blowout results for almost any other drugmaker.

But Eli Lilly’s case is different.

First, the company’s shares are richly valued, so investors’ expectations are sky-high. See the chart below. For context, the average forward price-to-earnings for the healthcare industry is 18.3.

Second, Eli Lilly cut its revenue and earnings per share guidance for the fiscal year 2024, something else investors don’t like. That explains the post-earnings sell-off.

But all of that should mean very little to long-term investors. The pace that Mounjaro and Zepbound are on is incredible, and there is more where that came from, with Eli Lilly set to earn more indications for tirzepatide, the active ingredient in both medicines.

Earlier this year, tirzepatide produced positive phase 3 results in treating sleep apnea and in reducing the risk of type 2 diabetes in overweight or obese prediabetic patients. Label expansions across both indications should come within the next 12 months.

Tirzepatide is undergoing several other studies. Further, Eli Lilly’s pipeline features other promising candidates, especially in weight loss.

Beyond its core areas of expertise, Eli Lilly has recently earned other important approvals, including Alzheimer’s disease treatment Kisunla, cancer drug Jaypirca, and ulcerative colitis therapy Omvoh.

Eli Lilly’s lineup and pipeline look too strong to disappoint in the long run. So, the company’s recent dip is a great opportunity for patient investors.

Source: The Motley Fool

[winston]

not vested

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?

by ALLISON GATLIN0

"We note that while RFK Jr. appears less optimistic on the use of incretins to curb the obesity crisis, he remains limited in his ability to influence either policy or pricing of obesity medications."

Sales of its tirzepatide-based drugs — Mounjaro and Zepbound — brought in a combined $4.37 billion. But that missed forecasts for $5.49 billion.

Zepbound alone to bring in more than $22.4 billion in 2029 sales.

J.P. Morgan analysts have said the market for weight-loss drugs could top $100 billion by 2030.

Source: IBD

https://www.investors.com/news/technolo ... src=A00220